|
Originally published In Press as doi:10.1074/jbc.M112366200 on March 4, 2002
J. Biol. Chem., Vol. 277, Issue 21, 18404-18410, May 24, 2002
Equilibrium Binding Assays Reveal the Elevated Stoichiometry
and Salt Dependence of the Interaction between Full-length Human
Sex-determining Region on the Y Chromosome (SRY) and DNA*
Stephanie
Baud ,
Emmanuel
Margeat §,
Serge
Lumbroso¶,
Françoise
Paris¶ ,
Charles
Sultan¶ ,
Catherine
Royer , and
Nicolas
Poujol **
From the Centre de Biochimie Structurale, UMR INSERM
554, CNRS 5048, Université Montpellier I, 29 rue de
Navacelles, 34090 Montpellier, France, ¶ INSERM U439, Pathologie
Moléculaire des Récepteurs Nucléaires, 70 rue de
Navacelles et Laboratoire d'Hormonologie, CHU Montpellier, 34295 Cedex
France, and Unité Endocrinologie Pédiatrique,
Hôpital A. de Villeneuve, CHU
Montpellier, 34295 Cedex France
Received for publication, December 26, 2001
 |
ABSTRACT |
In an effort to better define the molecular
mechanism of the functional specificity of human sex-determining region
on the Y chromosome (SRY), we have carried out equilibrium binding
assays to study the interaction of the full-length bacterial-expressed protein with a DNA response element derived from the CD3 gene enhancer. These assays are based on the observation of the fluorescence anisotropy of a fluorescein moiety covalently bound to the target oligonucleotide. The low anisotropy value due to the fast tumbling of
the free oligonucleotide in solution increases substantially upon
binding the protein to the labeled target DNA. Our results indicate
that the full-length human wild-type SRY (SRYWT)
forms a complex of high stoichiometry with its target DNA. Moreover, we
have demonstrated a strong salt dependence of both the affinity and
specificity of the interaction. We have also addressed the DNA bending
properties of full-length human SRYWT in solution by
fluorescence resonance energy transfer and revealed that maximal bending is achieved with a protein to DNA ratio significantly higher
than the classical 1:1. Oligomerization thus appears, at least in
vitro, to be tightly coupled to SRY-DNA interactions. Alteration of protein-protein interactions observed for the
mutant protein SRYY129N, identified in a patient presenting
with 46,XY sex reversal, suggests that oligomerization may play an
important role in vivo as well.
 |
INTRODUCTION |
Sex-determining region on the Y chromosome
(SRY)1 is the master genetic
switch that triggers development of the bipotential gonad into testes
in mammalian embryos (1, 2). The protein it encodes is a member of a
large family of nuclear proteins harboring a 79-amino acid motif known
as a high mobility group (HMG) box (3). HMG box-containing proteins can
be classified into two major groups based on the degree of sequence
specificity in DNA binding and the number of HMG boxes within a
protein. One group includes UBF, HMG-1 and MT-TF1, which have
multiple HMG boxes and recognize DNA with low or no specificity. The
other group includes transcriptional regulators such as LEF-1 and Sox
(SRY-box related) proteins, including SRY, that possess a single HMG
box and show sequence-specific DNA binding. Thus, the SRY protein is a
DNA-binding protein that recognizes certain AT-rich sequences (4-6)
including the consensus binding sequence A/TAACAAAT/A obtained by
random site selection (7). Upon binding, human SRYWT
induces a 60-83° bend in the DNA helix as demonstrated by circular
permutation assays (6, 8, 9), NMR structure (10), and fluorescence resonance energy transfer (11). Both DNA binding and bending capacities
were demonstrated as essential for testis development on the basis of
the study of the biochemical consequences of SRY mutations (4, 9, 12).
To date, 36 SRY mutations have been reported (13) in patients with
gonadal dysgenesis/XY sex reversal, and the large majority (33 of 36)
of the patients were phenotypically normal 46,XY females with complete
gonadal dysgenesis. The strong bending of DNA together with the lack of
a potential trans-regulation domain in human SRY has led to the
suggestion that the protein may modulate transcription by acting
architecturally in the assembly of a nucleoprotein complex (9).
However, despite the critical role of SRY in the cascade of gene
regulation leading to maleness, the direct targets of SRY remain to be
positively identified.
Because the first step in such a cascade is DNA recognition, a
thorough, quantitative understanding of the structure-energetic function relations in this system is essential. A number of studies of
the interactions between SRY and duplex DNA, all using mobility shift
assays, have been published (8, 9, 14, 15). For example, Ferrari
et al. (8) examined SRY-DNA interactions, but their study
was restricted to a construct containing only the HMG box. Similar
studies using wild-type and mutant SRY isolated from complete gonadal
dysgenesis have been performed but were still restricted to the SRY HMG
box (9). However, domains of SRY distinct from the HMG box have been
implicated in the modulation of DNA binding properties (16). Trimmer
et al. (15) have reported studies of full-length human
SRY and human SRY-HMG box domain interactions with a 20-bp DNA
oligonucleotide. Their results suggested that the affinities of both
constructs were in the nanomolar range but also pointed out sharp
binding transitions and higher order complexes with multiples sites on
the probes that precluded of a thermodynamic analysis with confidence.
The gel mobility shift method provides interesting information
concerning the number of stoichiometric complexes formed but suffers
from its nonequilibrium nature and the relatively large signal to noise
ratio inherent in the titration curves derived from quantification of
the bands. The quality of such data is usually insufficient for
determination of the presence and degree of cooperativity in binding.
In the present work, we have used a fluorescence-based binding assay to
quantitatively characterize the interaction between full-length
bacterial-expressed human SRY and its target DNA. Our equilibrium
assays are based on the observations of changes in the fluorescence
anisotropy of a fluorescein-labeled DNA target upon binding by the
protein. Because rotational diffusion of the free oligonucleotide is
quite rapid, the anisotropy of the fluorescent dye covalently bound to
the oligonucleotide is quite low, i.e. little orientation of
the polarized exciting light is retained in the emission. However,
because binding by the protein significantly slows the rotational
diffusion of the oligonucleotide, much more of the exciting light
polarization is retained in the emission. These experiments can be
performed with very low concentrations of target DNA and provide data
of very high precision and reproducibility (17-19). Thus, they can be
used to quantitatively characterize the affinity, cooperativity, and,
eventually, the kinetics of biomolecular interactions. To gain further
insight into the molecular basis for SRY function, we performed binding
experiments with a rare SRY mutant, identified in partial rather than
complete gonadal dysgenesis, that may present more subtle
biochemical consequences and thus be more difficult to reveal. Only
three SRY mutations have been reported to date with this partial
clinical presentation, and all of them were located outside the HMG box
(20-22). In contrast, the fourth such mutation (Y129N) examined here
is located at the C-terminal end of the HMG box.
We have used this anisotropy-based assay to evaluate the affinity,
specificity, and cooperativity of the interaction between the
full-length wild-type and mutant human SRY with the consensus target
DNA at various salt concentrations. We also addressed the DNA bending
properties of both full-length human SRYs in solution by fluorescence
resonance energy transfer (FRET).
 |
EXPERIMENTAL PROCEDURES |
Construction of the Plasmid pQE30-SRY--
His-tagged proteins
were overexpressed in Escherichia coli and purified by
nickel-nitrilotriacetic acid-agarose beads (Qiagen, Courtaboeuf,
France) under denaturing conditions. DNA encoding for the full-length
SRY protein was amplified from genomic DNA extracted from a fertile
subject and from the patient presenting with the Y129N substitution.
For this purpose, the oligonucleotides SRYs
(5'-TCACGGATCCATGCAATCATATGCTTCTG-3') and SRYas
(5'-CTAATTAAGCTTCAGCTTTGTCCAGTGGC-3') were purchased from Genosys
(Montigny-le-Bretonneux, France). Reaction products and expression
plasmid pQE30 (Qiagen) were cleaved with BamHI and
HindIII, purified, ligated, and cloned into E. coli XL1. The resulting plasmids pQE30-SRYWT and
pQE30-SRYY129N were checked by sequencing.
Protein Expression and Purification--
The plasmids were
introduced into E. coli SG13009-rep4 (Qiagen). The cells
were grown in LB medium with 100 µg/ml ampicillin and 25 µg/ml
neomycin at 37 °C and induced at an
A600 of 0.7 with 0.5 mM
isopropyl -D-thiogalactopyranoside. After 2h, the cells were harvested by centrifugation and lysed under denaturing conditions (6 M guanidine hydrochloride, 20 mM Tris-HCl,
pH 8.0, 5 mM imidazole, 500 mM NaCl, and 5 mM -mercaptoethanol). The cell lysates were passed over
a nickel-nitrilotriacetic acid-agarose column (Qiagen), and the SRY
proteins were eluted according to the manufacturer's recommendations
(6 M urea, 20 mM bis-Tris-HCl, pH 5.0, 200 mM imidazole, 500 mM NaCl, and 5 mM
-mercaptoethanol). The unfolded protein was subject to a
concentration under nitrogen (Amicon, YM10) and then added dropwise to
the renaturing buffer (10 mM Tris-HCl, pH 7.0, 150 mM NaCl, 1 mM EDTA, 5 mM
dithiothreitol, and 10% glycerol) at 0 °C on ice. The folded
proteins were then loaded on a fast protein liquid chromatography
Superdex 75 size exclusion column (AKTA prime; Amersham Biosciences).
The proteins eluted at the expected monomer molecular mass were
homogeneous by Coomassie Blue staining of a SDS-polyacrylamide gel, and
their respective concentrations were calculated by using the extinction coefficient (34640 M 1 cm 1 at
280 nm).
Oligonucleotides--
Oligonucleotides were purchased in
HPLC-purified form from Genset S.A. (Paris, France). The fluorescein
and rhodamine X labels were incorporated by the supplier using
phosphoramidite chemistry, and all the free probe was thus eliminated
in the synthesizer and subsequent HPLC purification. The labeling
ratios for the oligonucleotides were 60% and 99% for fluorescein- and
rhodamine X-labeled oligonucleotides, respectively. The sense and
antisense strands were annealed by heating a 1:1 molar ratio of
unlabeled antisense with fluorescein-labeled sense strands to 85 °C
for 5 min and slowly cooling them in a thermocycler (Gen-amp 2400; PerkinElmer Life Sciences), resulting in a duplex probe used for the
anisotropy assays (F-SRBE). A double-labeled duplex probe (F-SRBE-R)
intended for FRET was similarly prepared, except that the antisense
strand was rhodamine X-labeled. The 23-bp probe referred to here as
SRBE has the sequence given below for the sense strand :
5'-CCCTGCAGGTAACAATGTCGGCT-3'.
Anisotropy Assays--
Binding assays were performed using a
Beacon 2000 polarization instrument (Panvera Corp., Madison, WI)
regulated at 4 °C. Each point in the titration curves was obtained
by starting with 200 µl of a concentrated solution of SRY and 5 nM F-SRBE. Aliquots of 40 µl were successively removed
from the starter solution and replaced by 40 µl containing 5 nM F-SRBE. The buffer solution was 10 mM
Tris-HCl, 1 mM EDTA, 10% glycerol, 1 mM
dithiothreitol, pH 7.5 (TEGD buffer) and contained the indicated
concentration of KCl. Tubes were equilibrated at 4 °C for 5 min
before measurement, and the anisotropy was measured successively until
stabilized. The reported values are the average of five to seven
measurements after stabilization. Anisotropy is calculated as the ratio
of the difference between vertical and horizontal emission
intensities (I// and I ) normalized to the total
intensity: A = (I// I )/(I// + 2I )
DNA Bending by FRET--
Time-resolved fluorescence experiments
were performed in the frequency domain using ISS frequency domain
acquisition electronics (ISS Inc., Champaign, IL). The excitation light
was at 450 nm from the frequency doubled mode-locked output of a
Spectra Physics Tsunami Titanium-Saphir laser excited with the light of
a Millenia X diode-pumped laser. Pulse width was 2 ps at 4 MHz, and the
frequency response was measured at harmonic frequencies from 4 to 200 MHz. Emission was measured at 530 nm with a bandpass filter. For FRET, we used a DNA probe containing a fluorescent donor (fluorescein) at the
5' end of one strand and an acceptor (rhodamine X) at the 5' end of the
other strand. Labeled DNA concentration was 50 nM. The
labeling ratio for acceptor was 99%. The labeling ratio for donor was
lower (near 60%), but these unlabeled molecules were invisible when
monitoring donor quenching. Bending is detected as enhanced FRET
efficiency due to a decrease in end-to-end distance. FRET efficiency
was calculated from donor intensity in the absence and presence of
acceptor (ID and IDA) as E (E = 1 (IDA/ID)) and D-A distances (R) were calculated
from E using a Ro value for this D-A pair of 55 Å, E = Ro6/(Ro6 + R6) where Ro is the
characteristic transfer distance. Fits of the frequency response curves
in terms of an energy transfer model with a Gaussian distance
distribution were carried out using the Globals Unlimited Program
(Laboratory for Fluorescence Dynamics, Urbana, IL).
 |
RESULTS |
Purification of Full-length Human SRYs--
The
His-tagged full-length human SRYWT and SRYY129N
proteins were overexpressed in E. coli and purified by
nickel chelate affinity chromatography under denaturing conditions,
followed by renaturation and size exclusion chromatography as described under "Experimental Procedures." In comparison with molecular mass
standards and other proteins prepared in the laboratory, SRYs eluted as a peak centered at a molecular mass of
22-25 kDa. The molecular mass calculated from the sequence of the gene
expressed in E. coli is 25.7 kDa. It therefore appears that
full-length SRY is a monomer in solution in the 1-10 µM
concentration range under our purification conditions. The resulting
protein is homogeneous by Coomassie Blue staining of a
SDS-polyacrylamide gel. Typically, 2 liters of SRY culture yielded 2 ml
of a 4 to 8 × 10 6 M solution of
pure, native full-length SRY.
Full-length SRYWT Binds Specifically to a Fluorescent
Oligonucleotide--
The target oligonucleotide used was 23 bp in
length and derived from the CD3 gene enhancer, except that it bears
the sequence TAACAATG, which allows for 2-fold better binding of SRY
HMG box (9). Fig. 1a shows a
representative (one of four) anisotropy-based binding isotherm of the
5'-fluorescein-labeled SRY-responsive binding element (F-SRBE) at 2 nM with purified full-length SRYWT at 4 °C
in the presence of 50 mM KCl in the TEGD buffer. No change in fluorescence intensity accompanied the increase in anisotropy, and
lifetime measurements on the free and bound fluorescein-labeled oligonucleotide revealed an identical 4.2-ns decay. The anisotropy signal thus directly represents a molar quantity. The anisotropy profile for SRY binding to F-SRBE is characterized by an initial plateau for the unbound DNA, followed by a very cooperative anisotropy increase (<1 log unit) as SRY complexes with the fluorescein-labeled DNA and concluded by a long plateau for saturated binding. Under these
equilibrium conditions (target [DNA] < C1/2) the apparent
midpoint of binding C1/2 was near 12 nM, in
agreement with Trimmer et al. (15). As noted, the anisotropy
profile presented a sharp increase in the anisotropy from the initial
to saturating plateau between 4 and 30 nM
SRYWT, revealing a very large degree of cooperativity.
Simple binding of one protein molecule to the DNA would occur over a
range of 1.908 log units. Such a high degree of cooperativity rules out simple monomer binding to the target DNA oligonucleotide and
demonstrates the existence of an oligomeric SRY-DNA complex. The large
shift in the anisotropy values from the initial (95 × 10 3) to the saturating plateau (225 × 10 3), hardly compatible with a monomer binding to DNA,
supports this conclusion. We therefore attempted to define the
stoichiometry of the complex observed at the saturating plateau.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 1.
a, full-length SRYWT
interacts with F-SRBE. Representative experiment (one of four)
anisotropy-based binding isotherms of the 5'-fluorescein-labeled
SRY-responsive binding element (F-SRBE) at 2 nM with
purified full-length SRYWT at 4 °C in the presence of 50 mM KCl in TEGD buffer ( ). b, stoichiometric
titration of SRBE by SRYWT. Unlabeled SRBE at a
concentration of 45 nM was added to 5 nM
labeled F-SRBE (total concentration, 50 nM) and titrated by
SRYWT in TEGD buffer and 50 mM KCl at 4 °C.
The anisotropy value is observed to increase well beyond a 1:1
SRYWT/SRBE ratio.
|
|
Stoichiometric Titration--
Unlabeled SRBE at a concentration of
45 nM was added to 5 nM labeled F-SRBE (total
SRBE, 50 nM) and titrated by SRYWT. At 50 nM SRBE, the oligonucleotide concentration is 5-fold
greater than the apparent binding midpoint in Fig. 1a, thus
assuring stoichiometric binding conditions. In the resultant
stoichiometric profile (Fig. 1b), the anisotropy value is
observed to continue to increase well beyond a ratio of 1 SRYWT monomer/SRBE molecule, supporting the hypothesis that
the complex stoichiometry is not 1:1. In fact, the saturating plateau
was reached for a concentration between 295 and 364 nM
SRYWT, corresponding to a stoichiometry between 6 and 7 SRYWT molecules/SRBE oligonucleotide.
Specificity of the SRYwt-F-SRBE Interaction--
To
examine the specificity of the binding, the SRYWT-F-SRBE
complex was competed with an excess of unlabeled DNA oligonucleotides (either specific (SRBE) or nonspecific (DR5)). The latter is a 37-bp
double-stranded DNA used in the laboratory that bears recognition sequences for the retinoid X receptor-retinoic acid receptor
heterodimer and is devoid of any specific binding site for SRY. As
observed in Fig. 2a, an 8- and
a 40-fold excess of unlabeled SRBE induced shifts in the titration
curves to higher concentrations for the C1/2 (70 and 200 nM, respectively) in the presence of 50 mM KCl.
These results (7- and 40-fold displacement of the C1/2 by an 8- and a 40-fold excess of unlabeled specific DNA, respectively) clearly
demonstrate the equilibrium status of the interaction between
SRYWT and its target DNA under our experimental
conditions.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2.
a, equilibrium status of the binding
assays. Profiles for titration of F-SRBE (5 nM) by
SRYWT in the absence ( ) or presence of an 8-fold molar
excess ( ) and a 40-fold molar excess of unlabeled SRBE ( ) are
shown. The profiles were obtained in TEGD buffer at 4 °C. The
respective 7- and 40-fold displacements of the C1/2 clearly demonstrate
the equilibrium status of the SRYWT-SRBE interaction
under our experimental conditions. b, salt dependence of the
SRYWT-DNA interaction. Profiles for titrations of F-SRBE
obtained in the presence of 50 ( ), 100 ( ), 150 ( ), 200 ( ),
and 250 mM KCl ( ). The profiles were obtained in TEGD
buffer at 4 °C, and the DNA concentration was 5 nM.
c, increasing salt concentrations improves specificity.
Profiles for titrations of F-SRBE (5 nM) by
SRYWT in TEGD buffer and 50 mM KCl
(squares) or 250 mM KCl (triangles)
in the absence ( and ) and presence ( and ) of a 10-fold
molar excess of nonspecific DNA oligonucleotide at 4 °C are
shown.
|
|
Surprisingly, in very similar experiments, a 10-fold excess of
unlabeled nonspecific DR5 duplex DNA (Fig. 2c) resulted in a
large shift to a higher concentration of anisotropy increase (C1/2 = 200 nM), revealing a relatively low
specificity of the interaction between SRYWT and its target DNA under these low salt conditions. The specificity of the
SRYWT binding to F-SRBE was next examined in the
fluorescence anisotropy assays by using incremental increases in the
buffer salt concentration. Increasing salt concentration usually
reduces nonspecific protein-DNA affinity more strongly than specific
affinity by competing for interaction with the negatively charged
phosphate backbone (18, 23, 24). Increasing salt concentration in the
absence of competitor DNA (Fig. 2b) yielded profiles
exhibiting the same saturating plateau, consistent with a complex of
identical stoichiometry, but the apparent affinities decreased. At 50 mM KCl, for example, the C1/2 is 12 nM,
whereas at 150 mM KCl, it is ~40 and ~400
nM at 250 mM KCl. As can be seen in Fig.
2b, we note a loss of cooperativity at higher salt
concentrations that may arise from a salt effect on protein-protein
affinity. A striking effect of increasing the salt concentration on the complex specificity can be seen in Fig. 2c. Closed
triangles correspond to the binding of SRYWT to 5 nM F-SRBE in the presence of 250 mM KCl, and
the open triangles correspond to the same profile in the
presence of 50 nM (a 10-fold molar excess) unlabeled
nonspecific target DR5. At this salt concentration, we did not observe
the large shift of the binding profile to higher concentration observed with DR5 at 50 mM KCl (closed and open
squares). Thus, although SRYWT binds to its target DNA
with low specificity at low salt concentrations, presumably due to
substantial electrostatic contacts between the positively charged
SRYWT and negatively charged DNA, the interaction is of
lower overall affinity but becomes much more specific at higher salt concentration.
DNA Bending by FRET--
Protein-directed DNA bending is proposed
to facilitate the assembly of DNA-multiprotein preinitiation complexes
giving rise to architectural gene regulation. Such behavior is believed
to be a crucial property of SRY (9). Therefore, the complex we observed
should bend the target DNA. We have evaluated full-length SRYWT-induced DNA bending by FRET. This technique employs
the SRBE probe containing a fluorescent donor (fluorescein) at the 5'
end of the sense strand and an acceptor (rhodamine X) at the 5' end of
the antisense strand. In the absence of protein, for this
oligonucleotide, the distance separating the donor-acceptor pair is
~88 Å. Bending is detected as enhanced FRET efficiency due to
decreased end-to-end distance. We have analyzed DNA bending by FRET
using increasing amounts of full-length SRYWT, and thus we
have established a titration profile of the DNA bending property. Because the saturating anisotropy plateau was identical at all salt
concentrations tested, the stoichiometry and nature of the complex are
assumed to be similar. We thus evaluated the DNA bending properties of
SRYWT at the salt concentration (50 mM KCl)
that allowed complete saturation of 50 nM SRBE by
SRYWT compatible with our available concentrations of
protein. Increasing concentrations of SRYWT ranging from 0 to 800 nM (Fig.
3a) resulted in a decreased intensity of the donor emission (excited at 450 nm), indicating that
FRET occurred upon formation of the SRYWT-SRBE complex. We ascribe this result to protein-induced bending of target DNA.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
DNA bending by FRET. Emission
spectra from fluorescence titration experiments of 50 nM double-labeled F-SRBE-R with increasing concentrations
of full-length SRY at room temperature. a, F-SRBE-R at 50 mM KCl with increasing concentrations of SRYWT
from 0 to 800 nM. b, F-SRBE-R at 50 and 250 mM KCl in the presence or absence of 800 nM
SRYWT. c, F-SRBE-R at 50 mM KCl with
increasing concentrations of SRYY129N from 12.5 to 3000 nM.
|
|
To verify the energy transfer, lifetime measurements on the donor
fluorescence were carried out at several concentrations of
SRYWT. Binding of SRYWT to the double-labeled
F-SRBE-R caused marked changes to the donor fluorescence lifetime (Fig.
4a). In the free DNA, the mean
lifetime of the donor in absence of acceptor (F-SRBE) was 4.2 ns and
was unchanged upon protein binding. The presence of the acceptor
(F-SRBE-R) did not lead to a reduction in the donor's mean lifetime
for the free DNA, consistent with the distance of separation in the
linear oligonucleotide. The addition of increasing amounts of
SRYWT to the double-labeled target led to complex decay and
a progressive shortening of the amplitude-weighted average lifetime
(3.25 and 2.44 ns, respectively, at 50 and 100 nM
[SRYWT]) before reaching a plateau (0.90 ns for 200 nM [SRYWT]; Fig. 4b). The
fluorescence mean lifetime values were used to calculate FRET
efficiency (E) and the distance R between the dyes (Table
I). It can be seen from Figs. 3 and 4 that for a 1:1 stoichiometry (50 nM both F-SRBE-R and
SRYWT), very little FRET occurs, and thus maximal DNA
bending was not achieved. Saturation of the FRET signal and thus the
protein-induced DNA bending occur near a ratio of 4 SRY/DNA, indicative
of the existence of a multiprotein complex on DNA. It is noteworthy
that the FRET experiment also revealed DNA bending at elevated
salt concentration, as seen in Fig. 3b, but according to the
loss of affinity observed in the presence of 250 mM KCl,
the titration was not complete, and the maximal DNA bending could not
be achieved at high salt concentration.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 4.
FRET is confirmed by time-resolved
fluorescence. a, frequency response profiles of 50 nM F-SRBE-R at 50 mM KCl in the absence of SRY
( , phase; , modulation), in the presence of 800 nM
SRYWT ( , phase; , modulation), and in the presence of
3000 nM SRYY129N ( , phase; , modulation).
b, average (amplitude-weighted) fluorescence lifetime
obtained from triple exponential fit of the frequency response profiles
for F-SRBE-R in the presence of increasing concentrations of
SRYWT ( ) and SRYY129N ( ).
|
|
We also analyzed the lifetime data at saturating protein concentrations
in terms of a decay scheme that included FRET. Given the nonhomogeneous
character of the decay in the presence of protein evident in the raw
data (Fig. 4a), analysis in terms of a unique distance, R,
between the probes was not possible. In contrast, analysis in terms of
a distance distribution yielded a good fit to the data and a broad
distribution centered at 40 ± 25 Å. This is indicative of
structural and/or dynamic heterogeneity in the SRYWT-DNA complex.
DNA Binding and Bending Characteristics of Mutated
SRYY129N--
To investigate structural and energetic
features important in the function of SRY, we performed the same
experiments with an SRY mutant (Y129N) identified in a rare case of
partial gonadal dysgenesis. The anisotropy profile for
SRYY129N binding to F-SRBE at 50 mM KCl is
shown in Fig. 5a ( ).
Notably, the same large increase in the anisotropy values from the
initial to the saturating plateau as observed with the
SRYWT is consistent with an identical elevated
stoichiometry of the SRYY129N/F-SRBE complex. We also noticed that increasing salt concentration had a stronger effect on the
binding of the mutant. Whereas the difference in the C1/2 between 50 and 100 mM KCl was limited for SRYWT
(6-fold; Fig. 2b), it was far greater for the mutant
(30-fold; Fig. 5a). As observed from Fig. 5b, the
apparent affinity for the F-SRBE is only slightly lower for
SRYY129N as compared with SRYWT at 50 mM KCl (C1/2 = 50 nM versus
12 nM for SRYWT). However, the mutant protein
exhibits a significantly lower degree of cooperativity in binding under
these conditions.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 5.
Full-length SRYY129N interacts
with F-SRBE-R. a, salt dependence of the
SRYY129N-DNA interaction. Profiles for titrations of F-SRBE
obtained in the presence of 50 ( ), 100 ( ), 150 ( ), 200 ( ),
and 250 mM KCl ( ) are shown. The profiles were obtained
in TEGD buffer at 4 °C, and the DNA concentration was 5 nM. b, profiles for titrations of 5 nM F-SRBE by SRYWT ( ) and
SRYY129N ( ) in the presence of 50 mM KCl are
shown. c, profiles for titrations of 5 nM F-SRBE
by SRYWT ( ) and SRYY129N ( ) in the
presence of 100 mM KCl are shown.
|
|
Because at our available concentrations both SRY proteins could
saturate the DNA with the same apparent stoichiometry at 50 mM KCl, we tested whether substitution Y129N alters DNA
bending properties at this salt condition. DNA bending by full-length SRYY129N was evaluated by FRET under experimental
conditions identical to those described for SRYWT, except
that the titrations were continued above 800 nM
SRYY129N, until 3000 nM, to reach the
saturating plateau. Fig. 3c shows the emission spectra of a
representative titration experiment. It is clear from this large
decrease in donor fluorescence that FRET occurred. Analysis of the
lifetime data (Fig. 4a) in the presence of saturating mutant
protein in terms of a distributed D-A distance again yielded a broad
distribution with a slightly larger mean value than that seen for
SRYWT (Table I). Consistent with a lower overall affinity
for the mutant protein, the FRET titration was shifted to a higher
protein concentration (Fig. 4b). These results indicate that
although the affinity and cooperativity are lower for the mutant
protein than for SRYWT, the mutant protein, when bound,
induces similar structural changes in DNA.
 |
DISCUSSION |
We have used fluorescence anisotropy to examine the interaction of
full-length human SRY and its target DNA under equilibrium binding
conditions. Our results indicate that full-length human SRY forms a
complex of high stoichiometry (6 or 7) with its target DNA. Moreover,
we have demonstrated a strong salt dependence on both the affinity and
specificity of the interaction. At 50 mM KCl, the apparent
affinity, as judged by the concentration of half saturation of
full-length human SRYWT for its target DNA, is comparable
with that determined by electrophoretic mobility shift analysis under
60 mM NaCl by Trimmer et al. (15), namely, in
the nanomolar range. Nevertheless, at this salt concentration, the
interaction exhibits a low degree of specificity. Increasing the salt
concentration improves the specificity of the interaction, and under
buffer conditions near physiological salt concentrations, SRYWT exhibited a reasonable discrimination between its
potential target DNA and a nonspecific oligonucleotide. We note that
the increase in specificity is accompanied by a loss of both
cooperativity and affinity. Thus, under near physiological salt
concentrations, the affinity of SRYWT for its target DNA
seems to be closer to the micromolar range rather than the nanomolar range.
The influence of the salt concentration on the specificity of the
SRYWT-DNA interaction is similar to that observed for the interaction between the estrogen receptor and its target DNA (18, 24),
but one main difference should be noted. Whereas salt concentration affects the affinity, specificity, and stoichiometry of estrogen receptor-DNA interactions, the stoichiometry of SRYWT-DNA
complex appears to remain unchanged over the range of salt
concentrations tested because anisotropy plateau values remain
constant. We evaluated the stoichiometry of the SRYWT
-DNA complex to be far from 1:1, rather 6:1 or 7:1,
but the lack of accuracy of the stoichiometric titration does not allow
its precise determination. The unknown stoichiometry precludes us from
performing a complete thermodynamic analysis. In fact, the
characterization of the stoichiometry of biomolecular complexes can be
one of the most difficult tasks in advancing our understanding of these
interactions. A number of techniques are available, but each presents
its own advantages and disadvantages. Analytical ultracentrifugation
would require availability and micromolar concentrations of protein,
and several hours would be required for equilibrium measurements. The
limited stability of the protein precludes such an approach. Moreover, resolving the difference between complexes of 6:1 versus 7:1
stoichiometries with this method would not necessarily prove to be
trivial, given the one-third power dependence of the translational
diffusion coefficient on molecular mass. Size exclusion chromatography
would require a long column and thus unreasonably large amounts of
proteins in order to achieve, if possible, sufficient resolution. We
have previously used fluorescence correlation spectroscopy with photon counting histogram analysis to perform a direct measure of the stoichiometry of the estrogen receptor-co-activator complex (19). In
the case of the interaction of SRYWT with DNA, fluorescence correlation spectroscopy is not appropriate because the relatively low
affinity of the complex would require over 200 nM labeled SRYWT for 100% complexation, and this is outside the
single molecule limit. Moreover, the difference between 6 and 7 molecules/DNA should only yield a 15% variation in the molecular
brightness, which is probably difficult to discriminate with
confidence, particularly outside the single molecule limit.
Higher order SRBE-SRYWT complexes have been reported
previously using electrophoretic mobility shift analysis by several
authors (9, 11, 15, 25). In electrophoretic mobility shift analysis, in
addition to the classical 1:1 complex, others complexes of lower
mobility or no mobility could be observed. In almost all cases, these
complexes were not taken into account for the determination of the
affinity by the authors and were assumed to correspond to nonspecific
complexes (9, 11, 15). Nevertheless, Teo et al. (25) also
demonstrated the tendency of HMG boxes of SRY and other members of the
high mobility group protein to oligomerize when bound to DNA.
Furthermore, the addition of N- and C-terminal extensions to the HMG
boxes increases the DNA-induced oligomerization with both
non-sequence-specific (25) and sequence-specific (25, 26) HMG boxes.
Similarly, Trimmer et al. (15) observed an increase in
oligomerization between HMG box and full-length SRY. Thus,
oligomerization appears to be a common feature of HMG box-containing proteins and could be directly related to the function. Indeed, our
FRET evaluation of the DNA bending properties of full-length SRYWT reveals a higher FRET efficiency than observed for
the HMG box-DNA complex, consistent with an increased bend angle as
compared with the literature, including the one determined by a very
similar approach (11). Such a discrepancy could be due in part to the structural differences between complexes of truncated and full-length proteins because the addition of a C-terminal extension to the HMG box
of LEF-1 increases the bend angle (26). However, it could also be
related to the stoichiometry of the complex. Indeed, our titration of
DNA bending by FRET revealed that maximal bending was achieved with a
protein to DNA ratio significantly higher than 1:1, whereas the
previously reported bend angles were determined using the classical 1:1
ratio, despite the existence of a lower mobility complex in the
permutation gel experiment (9). Only Lnenicek-Allen et al.
(26) noticed that the second shifted complex of LEF-1 HMG box exhibited
an increased bend, from 57° to 125°.
The physiological relevance of such an oligomerization on DNA remains
to be clarified, but it is noteworthy that the differences observed
between SRYWT and the Y129N mutant concerned mainly the degree of binding cooperativity and the magnitude of salt-induced shifts. It is therefore likely that the differences in salt effects arise from differences in the salt dependence of protein-protein interactions rather than differences in protein-DNA binding. This and
the decreased binding cooperativity of the mutant point to a defect in
the protein-protein interactions induced by the mutation.
From a structural view point, the consequences of the substitution are
difficult to rationalize because the structure of full-length SRYWT remains to be determined; only the structure of
monomeric SRY-HMG in complex with DNA is available. Basing our
interpretation on this structure, the point mutation Y129N, due to the
C-terminal location of the Y129, would not affect the packing of
residues within the protein core that would be expected to destabilize the protein. Indeed, our mutant protein is stable, and its DNA binding
and bending properties, at least under low salt concentration conditions, indicate that it is active.
The modified protein-protein interaction induced by the substitution
strongly suggests the implication of Y129 in protein association,
although the effect may be indirect because Y129, in the NMR structure,
appears to be orthogonally oriented and in direct contact with the DNA
bases. Its proper location could be of crucial importance for the
correct orientation and positioning of the remaining C-terminal region
of SRY, which in turn could potentiate protein-protein association.
Moreover, Y129 is the last ordered residue observed in the NMR
structure, likely reflecting the need for further stabilization of the
C-terminal region of SRY.
Although the tendency of full-length human SRY to oligomerize will
require in vivo confirmation, one should bear in mind that, in many cases, formation of higher order oligomeric structures contributes crucially to protein functionality and regulation (27).
Single mutations in the tetramerization domain of the tumor suppressor
p53, for example, can inactivate the protein in a manner similar to
that seen with mutations in the DNA-binding domain (for review, see
Ref. 28). Oligomerization could also result in transcriptional
silencing such as that observed for TEL, a frequent target of
chromosomal translocation in a large number of hematological
malignancies, in which oligomerization mediates the spreading of
transcriptional repression complexes along the chromosome (29). Because
human SRY appears devoid of any transcriptional activation domain, and
no gene positively regulated by SRY has yet been identified, active
regulation of transcription by SRY remains a matter of debate. A
repressive mechanism, similar to the yeast HMG box-containing hypoxic
repressor Rox1 (30), cannot be excluded. This would perfectly match the hypothesis drawn by Fellous and co-workers (31, 32), who proposed that
SRY acts as a repressor of the expression or activity of an autosomal
recessive or X-linked locus termed Z that acts as a negative regulator
of the male determining pathway.
We have demonstrated here that 1) full-length human SRY binds as an
oligomeric complex to its target DNA and induces a strong bend, 2) SRY
protein-protein interactions are linked energetically to protein-DNA
interactions, 3) increasing salt concentration leads to a decrease in
DNA binding affinity and cooperativity linked to a loss of
protein-protein interaction, and 4) a functional mutant of SRY
resulting in a sex reversal phenotype exhibits similar stoichiometry
and DNA bending characteristics but impaired protein-protein cooperativity in DNA binding.
Thus, SRY function in vivo may be significantly more complex
than a simple interaction of its HMG box with target DNA. It is
possible that the overall architecture of these higher order complexes
underlies the fundamental mechanism of SRY action in sexual differentiation.
 |
FOOTNOTES |
*
This work was supported in part by the CNRS, INSERM, La
Fondation pour la Recherche Médicale, L'Association pour la
Recherche sur le Cancer, and the Région Languedoc-Roussillon.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by a doctoral grant from the French Ministère de
l'Education, de la Recherche et de la Technologie and a grant from the
Fondation pour la Recherche Médicale.
**
A postdoctoral fellow (INSERM poste d'accueil recherche clinique).
To whom correspondence should be addressed. Present address: Centre
Biologique Médical, Laboratoire d'Analyses Médicales, 16 rue du 8 Mai 1945, Sète, 34200 France. Tel.:
33-467-748-317; Fax: 33-467-181-667; E-mail:
poujol-at-home@wanadoo.fr.
Published, JBC Papers in Press, March 4, 2002, DOI 10.1074/jbc.M112366200
 |
ABBREVIATIONS |
The abbreviations used are:
SRY, sex-determining
region on the Y chromosome;
FRET, fluorescence resonance energy
transfer;
HMG, high mobility group;
HPLC, high pressure liquid
chromatography.
 |
REFERENCES |
| 1.
|
Sinclair, A. H.,
Berta, P.,
Palmer, M. S.,
Hawkins, J. R.,
Griffiths, B. L.,
Smith, M. J.,
Foster, J. W.,
Frischauf, A. M.,
Lovell-Badge, R.,
and Goodfellow, P. N.
(1990)
Nature
346,
240-244[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Berta, P.,
Hawkins, J. R.,
Sinclair, A. H.,
Taylor, A.,
Griffiths, B. L.,
Goodfellow, P. N.,
and Fellous, M.
(1990)
Nature
348,
448-450[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Baxevanis, A. D.,
and Landsman, D.
(1995)
Nucleic Acids Res.
23,
1604-1613[Abstract/Free Full Text]
|
| 4.
|
Harley, V. R.,
Jackson, D. I.,
Hextall, P. J.,
Hawkins, J. R.,
Berkovitz, G. D.,
Sockanathan, S.,
Lovell-Badge, R.,
and Goodfellow, P. N.
(1992)
Science
255,
453-456[Abstract/Free Full Text]
|
| 5.
|
Haqq, C. M.,
King, C. Y.,
Donahoe, P. K.,
and Weiss, M. A.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
1097-1101[Abstract/Free Full Text]
|
| 6.
|
Giese, K.,
Pagel, J.,
and Grosschedl, R.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3368-3372[Abstract/Free Full Text]
|
| 7.
|
Harley, V. R.,
and Goodfellow, P. N.
(1994)
Mol. Reprod. Dev.
39,
184-193[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Ferrari, S.,
Harley, V. R.,
Pontiggia, A.,
Goodfellow, P. N.,
Lovell-Badge, R.,
and Bianchi, M. E.
(1992)
EMBO J.
11,
4497-4506[Medline]
[Order article via Infotrieve]
|
| 9.
|
Pontiggia, A.,
Rimini, R.,
Harley, V. R.,
Goodfellow, P. N.,
Lovell-Badge, R.,
and Bianchi, M. E.
(1994)
EMBO J.
13,
6115-6124[Medline]
[Order article via Infotrieve]
|
| 10.
|
Werner, M. H.,
Huth, J. R.,
Gronenborn, A. M.,
and Clore, G. M.
(1995)
Cell
81,
705-714[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Ukiyama, E.,
Jancso-Radek, A., Li, B.,
Milos, L.,
Zhang, W.,
Phillips, N. B.,
Morikawa, N.,
King, C. Y.,
Chan, G.,
Haqq, C. M.,
Radek, J. T.,
Poulat, F.,
Donahoe, P. K.,
and Weiss, M. A.
(2001)
Mol. Endocrinol.
15,
363-377[Abstract/Free Full Text]
|
| 12.
|
Nasrin, N.,
Buggs, C.,
Kong, X. F.,
Carnazza, J.,
Goebl, M.,
and Alexander-Bridges, M.
(1991)
Nature
354,
317-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Schaffler, A.,
Barth, N.,
Winkler, K.,
Zietz, B.,
Rummele, P.,
Knuchel, R.,
Scholmerich, J.,
and Palitzsch, K. D.
(2000)
J. Clin. Endocrinol. Metab.
85,
2287-2292[Abstract/Free Full Text]
|
| 14.
|
Peters, R.,
King, C. Y.,
Ukiyama, E.,
Falsafi, S.,
Donahoe, P. K.,
and Weiss, M. A.
(1995)
Biochemistry
34,
4569-4576[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Trimmer, E. E.,
Zamble, D. B.,
Lippard, S. J.,
and Essigmann, J. M.
(1998)
Biochemistry
37,
352-362[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Desclozeaux, M.,
Poulat, F.,
de Santa Barbara, P.,
Soullier, S.,
Jay, P.,
Berta, P.,
and Boizet-Bonhoure, B.
(1998)
Biochim. Biophys. Acta
1397,
247-252[Medline]
[Order article via Infotrieve]
|
| 17.
|
Grillo, A. O.,
Brown, M. P.,
and Royer, C. A.
(1999)
J. Mol. Biol.
287,
539-554[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Boyer, M.,
Poujol, N.,
Margeat, E.,
and Royer, C. A.
(2000)
Nucleic Acids Res.
28,
2494-2502[Abstract/Free Full Text]
|
| 19.
|
Margeat, E.,
Poujol, N.,
Boulahtouf, A.,
Chen, Y.,
Muller, J. D.,
Gratton, E.,
Cavailles, V.,
and Royer, C. A.
(2001)
J. Mol. Biol.
306,
433-442[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Brown, S., Yu, C.,
Lanzano, P.,
Heller, D.,
Thomas, L.,
Warburton, D.,
Kitajewski, J.,
and Stadtmauer, L.
(1998)
Am. J. Hum. Genet.
62,
189-192[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Domenice, S.,
Yumie Nishi, M.,
Correia Billerbeck, A. E.,
Latronico, A. C.,
Aparecida Medeiros, M.,
Russell, A. J.,
Vass, K.,
Marino Carvalho, F.,
Costa Frade, E. M.,
Prado Arnhold, I. J.,
and Bilharinho Mendonca, B.
(1998)
Hum. Genet.
102,
213-215[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
McElreavey, K.,
Vilain, E.,
Barbaux, S.,
Fuqua, J. S.,
Fechner, P. Y.,
Souleyreau, N.,
Doco-Fenzy, M.,
Gabriel, R.,
Quereux, C.,
Fellous, M.,
and Berkovitz, G. D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8590-8594[Abstract/Free Full Text]
|
| 23.
|
Record, M. T., Jr., Ha, J. H.,
and Fisher, M. A.
(1991)
Methods Enzymol.
208,
291-343[Medline]
[Order article via Infotrieve]
|
| 24.
|
Ozers, M. S.,
Hill, J. J.,
Ervin, K.,
Wood, J. R.,
Nardulli, A. M.,
Royer, C. A.,
and Gorski, J.
(1997)
J. Biol. Chem.
272,
30405-30411[Abstract/Free Full Text]
|
| 25.
|
Teo, S. H.,
Grasser, K. D.,
and Thomas, J. O.
(1995)
Eur. J. Biochem.
230,
943-950[Medline]
[Order article via Infotrieve]
|
| 26.
|
Lnenicek-Allen, M.,
Read, C. M.,
and Crane-Robinson, C.
(1996)
Nucleic Acids Res.
24,
1047-1051[Abstract/Free Full Text]
|
| 27.
|
Engel, J.,
and Kammerer, R. A.
(2000)
Matrix Biol.
19,
283-288[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Chene, P.
(2001)
Oncogene
20,
2611-2617[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Kim, C. A.,
Phillips, M. L.,
Kim, W.,
Gingery, M.,
Tran, H. H.,
Robinson, M. A.,
Faham, S.,
and Bowie, J. U.
(2001)
EMBO J.
20,
4173-4182[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Deckert, J.,
Khalaf, R. A.,
Hwang, S. M.,
and Zitomer, R., S.
(1999)
Nucleic Acids Res.
27,
3518-3526[Abstract/Free Full Text]
|
| 31.
|
McElreavey, K.,
Vilain, E.,
Abbas, N.,
Herskowitz, I.,
and Fellous, M.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
3368-3372[Abstract/Free Full Text]
|
| 32.
|
Veitia, R. A.,
Salas-Cortes, L.,
Ottolenghi, C.,
Pailhoux, E.,
Cotinot, C.,
and Fellous, M.
(2001)
Mol. Cell. Endocrinol.
179,
3-16[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|